ADL-5859

DB18910InvestigationalSmall molecule

ADL-5859 is under investigation in clinical trial NCT00626275 (Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis).

Mechanism: Pharmacologically active on Delta-type opioid receptor
Curator reviewed
Formula / weight: C₂₄H₂₈N₂O₃ · 392.499 g/mol (avg)
Also known as: BENZAMIDE, N,N-DIETHYL-4-(5-HYDROXYSPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDIN)-4-YL)-
Code names: ADL-5859

Resolves to

Compound

UNIIFA554TW3UPCAS850305-06-5ChEMBLCHEMBL494480

Structure

InChIKeyOPIKUXLJQFYMSC-UHFFFAOYSA-NSMILESCCN(CC)C(=O)C1=CC=C(C=C1)C1=CC2(CCNCC2)OC2=CC=CC(O)=C12

Targets

P41143OPRD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with ADL-5859, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account